Ionis Pharmaceut

Shares of Ionis Pharmaceuticals fell to a new 52-week low of $50.00, about 35% below the level at the start of the year; market capitalization is roughly $8.45 billion. Falling prices reflect both broader market conditions and company-specific issues, notably disappointing study data for the drug Pelacarsen. Several analysts subsequently cut their price targets and removed expected milestone and licensing payments, though some maintained buy recommendations. » Plus sur de.investing.com

At the Wells Fargo Healthcare Conference Ionis highlighted commercial progress: two in-house FDA approvals in 2024 (TRYNGALZA, ZANVASTRO) and an upcoming GSK approval for chronic hepatitis B. The TRYNGALZA launch is outperforming expectations with strong prescription momentum, payer acceptance and a U.S. revenue potential of over $3 billion. At the same time, Pelacarsen (Lp(a)) and Eplontersen (ATTR cardiomyopathy) missed primary endpoints, increasing pipeline risk; however, Eplontersen monotherapy subgroups still show positive signals. Ionis is advancing next‑gen candidates such as ION775 and remains committed to long‑term revenue targets for TRYNGALZA and DAWNZERA. » Plus sur de.investing.com

Ionis Pharmaceuticals' stock fell about 13% premarket after the Phase‑3 Lp(a)HORIZON trial of Pelacarsen, developed with Novartis, failed. Although Pelacarsen lowered Lipoprotein(a) levels, it did not significantly reduce the combined risk of cardiovascular death, heart attack, stroke or urgent revascularization. As a result, expected future licensing and milestone payments to Ionis will likely not materialize and the stock is approaching its 52‑week low; analysts say the downside is partly limited by the rest of the pipeline and recent approvals. » Plus sur de.investing.com